|Improving Patient Outcomes in Myelofibrosis: Writing the Next Chapter in the JAK Inhibitor Story|
CME, CPE, CNE
Srdan Verstovsek, MD, PhD – Chair; Rami S. Komrokji, MD; Prithviraj Bose, MD
|Release Date: October 09, 2019|
Expiration Date: October 09, 2020
As outcomes for myelofibrosis patients remain suboptimal and treatment options are limited, it is important now more than ever for clinicians to keep abreast of the potential and emerging treatment options. This collaborative peer-to-peer exchange will draw on the collective experience of our three leading experts in research and treatment of patients with myelofibrosis. This activity focuses on the current, newly approved, and emerging JAK inhibitors, including sharing best practices and emerging data from clinical trials.
This activity was previously presented on September 13, 2019 to a live audience during the SOHO 2019 Annual Meeting in Houston, Texas. Please note: If you attended the live meeting or simulcast viewing, you are ineligible to receive an additional 1.0 contact hour of credit and may not re-submit for credit previously awarded.Provided by MediCom Worldwide, Inc.
Supported by educational grants from Celgene Corporation and Incyte Corporation.
|Begin, Earn CreditView Only, No Credit|